All In Biotech

Drug Trial Radar · NCT07598708

A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence

A Randomized, Double-blind, 3-Arm Parallel Design Study to Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Cleminorexton Compared With Placebo in Participants With Central Disorders of Hypersomnolence

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 222 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

222

Planned (sponsor's estimate)

Start

May 29, 2026

Primary completion

Sep 30, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
May 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Narcolepsy Type 1 (NT1) and Narcolepsy Type 2 (NT2) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness \[EDS\]). People living with these conditions might find it hard to stay alert and pay attention when they are at school, working, driving, or performing other daily activities. While all conditions result in feeling sleepy, there are some differences in other common symptoms: * NT1: People with NT1 often feel very tired during the day and experience cataplexy. Cataplexy is a sudden loss of muscle strength, which can cause someone to collapse or lose control of their muscles for a short time. This is often triggered by strong emotions, such as laughter or surprise. They may also have trouble sleeping well at night. * NT2: People with NT2 feel sleepy during the day, just like NT1, but they do not have cataplexy. Orexin is a protein in the brain that helps coordinate a system that plays an important role in helping people to stay awake during the daytime. Cleminorexton is designed to mimic the action of orexin. The purpose of this study is to see how safe and tolerable cleminorexton is in NT1 and NT2 and learn about what the drug does to the body. Another goal of the study is to see if cleminorexton can help people with NT1 and NT2 feel less sleepy and make other symptoms better.

Conditions

  • Narcolepsy Type 1
  • Narcolepsy Type 2

Interventions

  • cleminorextonDrug

    Oral cleminorexton capsule

  • PlaceboDrug

    matching placebo capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in mean sleep latency (average of the first 4 trials) on the Maintenance of Wakefulness Test (MWT)Time frame: Baseline to week 12

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Birmingham, Alabama

    Birmingham, Alabama · Recruiting

  • Colorado Springs, Colorado

    Colorado Springs, Colorado · Recruiting

  • Brandon, Florida

    Brandon, Florida · Recruiting

  • Miami, Florida

    Miami, Florida · Recruiting

  • Miami, Florida

    Miami, Florida · Recruiting

  • Miami, Florida

    Miami, Florida · Recruiting

  • Miami, Florida

    Miami, Florida · Recruiting

  • Miami Lakes, Florida

    Miami Lakes, Florida · Recruiting

  • Orlando, Florida

    Orlando, Florida · Recruiting

  • St. Petersburg, Florida

    St. Petersburg, Florida · Recruiting

  • Atlanta, Georgia

    Atlanta, Georgia · Recruiting

  • Rincon, Georgia

    Rincon, Georgia · Recruiting

  • Stockbridge, Georgia

    Stockbridge, Georgia · Recruiting

  • Lansing, Michigan

    Lansing, Michigan · Recruiting

  • Flowood Mississippi

    Flowood, Mississippi · Recruiting

  • Denver, North Carolina

    Denver, North Carolina · Recruiting

  • Huntersville, North Carolina

    Huntersville, North Carolina · Recruiting

  • Cincinnati, Ohio

    Cincinnati, Ohio · Recruiting

  • Dublin, Ohio

    Dublin, Ohio · Recruiting

  • Columbia, South Carolina

    Columbia, South Carolina · Recruiting

  • Austin, Texas

    Austin, Texas · Recruiting

  • Dallas, Texas

    Dallas, Texas · Recruiting

  • Frisco, Texas

    Frisco, Texas · Recruiting

  • Houston, Texas

    Houston, Texas · Recruiting

  • San Antonio, Texas

    San Antonio, Texas · Recruiting

  • Sugar Land, Texas

    Sugar Land, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.